

Sleeping Sickness - Human African Trypanosomiasis (HAT) Market

Market Research Report | 2023-10-27 | 33 pages | BCC Research

AVAILABLE LICENSES:

- Single User License \$3500.00
- 2-5 Users License \$4200.00
- Site License \$5040.00
- Enterprise License \$6048.00

Report description:

Description

Report Scope:

The market for sleeping disorders will be thoroughly covered in the current report. The epidemiology, geographical markets, and market trends for sleeping sickness are examined in this paper. This study will highlight the present sleeping sickness market and provide a thorough analysis of the market's competitive landscape.

Report Includes:

- An overview and up-to-date analysis of the global sleeping sickness market
- Analyses of the global market trends, with historical market revenue data (sales figures) from 2020 to 2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Estimate of the actual market size and revenue forecast for the global sleeping sickness market in USD millions, and corresponding market share analysis based on diagnosis type, treatment modality, and geographic region
- In-depth information (facts and figures) pertaining to the market growth drivers, opportunities and challenges, upcoming technologies, future prospects, and regulatory scenarios; and the impacts of COVID-19 and the Russia-Ukraine war on the market
- Discussion of the importance of ESG in sleeping sickness market, including consumer attitudes, impact of ESG factors on company performance, and the ESG practices followed
- Identification of the major stakeholders, and analysis of their company competitive landscape based on news/developments, company financials, competitive strategies, and operational integration
- Company profiles of major players within the industry

Executive Summary

Scotts International. EU Vat number: PL 6772247784

Summary:

Human African trypanosomiasis (HAT) is still a problem in many sub-Saharan African nations, especially in areas with poor infrastructure and resources for treatment. Although the disease has been somewhat controlled, work still needs to be done to completely eradicate it, and vigilante measures must be taken to avoid a comeback. The funding from governments, NGOs and pharmaceutical firms for HAT research and development is increasing. Improved diagnostic equipment, therapies, and preventative measures are likely to be the outcome of this.

The tsetse fly spreads this disease in humans by biting and feeding on blood. The Diptera order contains the Glossina vector. Because Glossina are viviparous, both the male and the female can transmit disease. The transmission of parasites is carried out by numerous subgenus flies, including G. palpalis palpalis, G. p. gambiensis, and G. morsitans, which transmits T. b. rhodesiense. For these flies to live, specific temperatures and relative humidity ranges of 50% to 80% are required. The Glossina, however, is categorized as a "bad vector" since the female only produces 10 larvae in her lifetime and because it loses parasites at every blood feeding.

The symptoms of T. b. gambiense and T. b. rhodesiense are frequently the same, although their frequency, severity, and kinetic appearance vary. HAT clinically develops in two stages. In fact, T. b. rhodesiense can result in patient mortality within six months, but T. b. gambiense patients can survive for more than 10 years.

Table of Contents:

Table of Contents

Chapter 1 Introduction

Overview

Study Goals and Objectives

Reasons for Doing This Study

Scope of Report

Information Sources

Geographic Breakdown

Chapter 2 Summary and Highlights

Chapter 3 Market Overview

History

Distribution Trends

HAT Causing Parasites

Clinical Features of HAT

Diagnosis of HAT

Antibody Detection

Parasite Detection

Future Perspectives

Population Screening

Chapter 4 Sleeping Sickness by Disease Types

Overview

Trypanosoma Brucei Gambiense

Diagnosis of T. b. Gambiense

Trypanosoma Brucei Rhodesiense

Diagnosis of T. b. Rhodesiense

Chapter 5 Sleeping Sickness by Treatments

Scotts International, EU Vat number: PL 6772247784

Overview
Drugs for HAT Treatment
Product Pipeline
Chapter 6 Competitive Landscape
Competitive Analysis
Chapter 7 Company Profiles
BAYER AG
SANOFI

Chapter 8 Appendix: Acronyms



Print this form

To place an Order with Scotts International:

Sleeping Sickness - Human African Trypanosomiasis (HAT) Market

Market Research Report | 2023-10-27 | 33 pages | BCC Research

☐ - Complete the rele	evant blank fields and sign				
 Send as a scanned email to support@scotts-international.com 					
ORDER FORM:					
Select license	License			Price	
	Single User License			\$3500.00	
	2-5 Users License			\$4200.00	
	Site License			\$5040.00	
	Enterprise License			\$6048.00	
			VAT		
			Total		
*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.					
** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numb					
se added at a					
Email*		Phone*			
First Name*		Last Name*			
Job title*					
Company Name*		EU Vat / Tax ID / NIP number*			
Address*		City*			
Zip Code*		Country*			
		Date	2025-05-14		

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com www.scotts-international.com

Signature

Scotts International. EU Vat number: PL 6772247784